Moderna’s stock jumps after biotech raises sales outlook
The company lifted its revenue outlook for the year, saying it expects revenue to grow as much as 25% in 2026.
Covered in this story
Analyst targets on Moderna
- Citi: $193 → $80 by Sep 2027 · Sell via 247wallst.com
- Rothschild & Co Redburn: $149 → $81 by Sep 2027 · Sell via Investing.com
- Morgan Stanley: $174 → $89 by Aug 2027 · Equalweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRNA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Moderna →Dalsna Finance is currently tracking 6 stories mentioning Moderna, the earliest published 20 Aug 2026.
Summary aggregated from MarketWatch's public RSS feed. The full reporting belongs to MarketWatch — please read it on their site.